Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL

Key clinical point: The study was halted early because of short-lived response and disease hyperprogression.

Major finding: Median progression-free survival was 2.7 months, and median overall survival was 6.7 months

Study details: An interim analysis of a phase 2 trial with 12 patients with peripheral T-cell lymphomas.

Disclosures: ­The study was supported by Bristol-Myers Squibb. Dr. Bennani reported research funding and advisory board activities for Bristol-Myers Squibb and others.


Bennani NN et al. ASCO 2019, Abstract 467.